Identification of Predictive Gene Expression Profile of Sunitinib Response in Metastatic Clear Cell Renal Carcinomas

Overview

Renal cell carcinoma accounts for 2-3% of all cancers in western countries. Brazilian kidney cancer data show an incidence of 6,270 new cases for 2018. New target-molecular therapies have emerged in recent years for the treatment of metastatic kidney cancer. Due to the heterogeneity of these patients and the lack of specific markers, therapeutic is currently based on clinical and laboratory analysis. The research for predictive biomarkers may better characterize the kidney cancer therapeutic management. The objectives are to identify a predictive gene expression profile in patients with advanced clear cell renal carcinoma treated with first-line sunitinib and correlate it with rate response, seeking to identify a predictive gene expression profile. As secondary objectives, the investigators will compare the gene expression profile found, with global survival and clinical-pathological characteristics. Materials and methods: To determine through systematic data collection the epidemiological profile, clinical-pathological characteristics, response rate, disease free survival and overall survival of 60 patients with metastatic clear cell renal carcinoma who used sunitinib in the first line between 2009 and 2018 at the Barretos Cancer Hospital. For evaluation of gene expression profile, the investigators will use a panel of a panel with 770 genes related to disease progression using nanostring technology. Keywords: Renal Cell Carcinoma; Sunitinib; Biomarkers; Gene expression; Nanostring.

Full Title of Study: “Identification of Predictive Gene Expression Profile of Sunitinib Rate Response in Metastatic Clear Cell Renal Carcinomas”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: February 20, 2020

Interventions

  • Diagnostic Test: Gene expression test using nanostring technology.
    • Evaluation of gene expression profile of a panel with 770 genes related to disease progression using nanostring technology

Arms, Groups and Cohorts

  • Responders
    • Those who present complete response, partial response, or stable disease, according to RECIST 1.1.
  • Not responders
    • Those who present progression disease according to RECIST 1.1.

Clinical Trial Outcome Measures

Primary Measures

  • Identify differentially expressed genes in two groups of objective response rate.
    • Time Frame: One year
    • Identify differentially expressed genes, through the nanoString platform, in two groups of objective response rate defined using the RECIST 1.1 criteria.

Secondary Measures

  • Epidemiological characterization of the metastatic clear cell renal carcinoma population treated with sunitinib in the first line, from Barretos Cancer Hospital.
    • Time Frame: One Year
    • Epidemiological characterization of the metastatic clear cell renal carcinoma population treated with sunitinib in the first line, from Barretos Cancer Hospital and correlate with data from differentially expressed genes.

Participating in This Clinical Trial

Inclusion Criteria

  • Adult patients – At least 18 years – Metastatic clear cell renal carcinoma – Primary tumors sample of nephrectomy or core biopsy Exclusion Criteria:

  • insufficient sample for molecular analysis – Patients with no record of treatment response data – Patients with a history of previous systemic treatment for Metastatic clear cell renal carcinoma – Patients with second primary synchronic or metachronic tumor undergoing treatment – Patients having received less than one cycle of sunitinib in the first line – Patients have received previous adjuvant and/or neoadjuvant treatment with an interval < 1 year between the end of treatment and the diagnosis of metastasis.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Barretos Cancer Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Andre Octavio Nicolau Sanches, Medical Doctor – Barretos Cancer Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.